European Urology Oncology

Slides:

Advertisements

Similar presentations

Debra Freeman, MD – Naples Christopher King, MD, PhD - Stanford.

Advertisements

125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy Mira Keyes, MD, Tom Pickles, MD, Alexander Agranovich, MD, Winkle.

Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards Charles S. Mayo, PhD, John.

Automatic treatment planning improves the clinical quality of head and neck cancer treatment plans Christian Rønn Hansen, Anders Bertelsen, Irene Hazell,

The PSA Era is not Over for Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Figure 1. Age Standardized Rate of Oropharyngeal Squamous Cell Carcinoma (OPSCC) in the UK, Data courtesy of the UK HPV Prevalence Study (1)

Chad G. Rusthoven, MD, Christine F. Lauro, MD, Brian D

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 1, Pages (July 2016)

Volume 66, Issue 4, Pages (October 2014)

Volume 70, Issue 4, Pages (October 2016)

Volume 68, Issue 1, Pages (July 2015)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

European Urology Oncology

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Marcel J. Steggerda, Henk G. van der Poel, Luc M.F. Moonen

Volume 67, Issue 6, Pages (June 2015)

Automatic treatment planning improves the clinical quality of head and neck cancer treatment plans Christian Rønn Hansen, Anders Bertelsen, Irene Hazell,

The PSA Era is not Over for Prostate Cancer

Yuanshan Cui, Yong Zhang European Urology

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Figure 4 Dosimetric comparison of LDR‑BT versus HDR‑BT

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer Nancy El-Bared, MD,

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

Radiation Therapy for Prostate Cancer

Volume 71, Issue 5, Pages (May 2017)

VMAT radiation-induced nausea and vomiting in adjuvant breast cancer radiotherapy: The incidental effect of low-dose bath exposure G. Lazzari, A. Terlizzi,

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Half-Body Irradiation With Tomotherapy for Pain Palliation in Metastatic Breast Cancer Carlo Furlan, MD, Marco Trovo, MD, Annalisa Drigo, ScD, MPh, Elvira.

Physics and Imaging in Radiation Oncology

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Volume 70, Issue 1, Pages (July 2016)

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review Alexey Surov, Hans Jonas Meyer, Andreas.

Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis Joseph Sargon Joseph, Vincent.

European Urology Oncology

Volume 69, Issue 1, Pages (January 2016)

European Urology Oncology

Axel Heidenreich European Urology Supplements

Clinical and radiobiological evaluation of a method for planning target volume generation dependent on organ-at-risk exclusions in magnetic resonance.

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Highlighting Unmet Needs: Real Patients, Difficult Choices

Nicholas Trakul, MD, PhD, Jeremy P

Management of Prostate Cancer: Global Strategies

Fernando P. Secin, Fernando J. Bianco, Nicholas T

Volume 74, Issue 6, Pages (December 2018)

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Figure 3 Target volume definitions

Oncoforum Urology: Prostate Cancer 2008 at a Glance

European Urology Oncology

Technical Innovations and Patient Support in Radiation Oncology

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Axel Heidenreich European Urology Supplements

Technical Innovations and Patient Support in Radiation Oncology

Clinical and Translational Radiation Oncology

European Urology Oncology

Stereotactic Body Radiotherapy for Central Lung Tumors

Volumetric and dosimetric comparison of two delineation guidelines for the radiation treatment of laryngeal squamous cell carcinoma C. Bondue, S. Racadot,

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

European Urology Oncology Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes Donald B. Fuller, Aaron D. Falchook, Tami Crabtree, Brent L. Kane, Clinton A. Medbery, Kelly Underhill, James R. Gray, Anuj Peddada, Ronald C. Chen European Urology Oncology DOI: 10.1016/j.euo.2018.06.013 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 Mid axial section of (A) a typical SBRT contour and (B) treatment plan for a patient with intermediate-risk prostate cancer (Gleason score 7 with left-sided involvement, with corresponding larger GTV to PTV expansion on that side). In (A) the GTV is outlined in red, PTV in green, and peripheral-zone tuning structure in blue. In (B) the 38-Gy prescription isodose line is in yellow, and the 125%, 150% and 75% isodose lines in white, red, and green, respectively. The isodose morphology is intended to substantially recapitulate that of high-dose-rate brachytherapy. For the entire cohort, the median prostate volume receiving >150% of the prescribed dose was 11.7% (range 0.1–32.2%). GTV=gross tumor volume; PTV=planning target volume. European Urology Oncology DOI: (10.1016/j.euo.2018.06.013) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Median prostate-specific antigen (PSA) over time for the overall trial population. The median and interquartile range are plotted. European Urology Oncology DOI: (10.1016/j.euo.2018.06.013) Copyright © 2018 The Authors Terms and Conditions

Fig. 3 Freedom from biochemical recurrence for the overall trial population and stratified by risk group. European Urology Oncology DOI: (10.1016/j.euo.2018.06.013) Copyright © 2018 The Authors Terms and Conditions

Fig. 4 Patient-reported quality of life. The mean and standard deviation are plotted. The minimally clinically important difference (MCID) for the EPIC-26 questionnaire has been defined as 10–12 points in the sexual domain, 6 points for urinary incontinence, 5 points for urinary irritation and obstruction, and 4 points for the bowel domain [16]. (A) Urinary irritation or obstruction score. (B) Urinary incontinence score. (C) Bowel score. (D) Sexual score. CI=confidence interval. European Urology Oncology DOI: (10.1016/j.euo.2018.06.013) Copyright © 2018 The Authors Terms and Conditions